LingCCYorkeEFuksZ. From IMRT to IGRT: Frontierland or neverland?Radiother Oncol2006; 78: 119–122.
2.
FowlerJF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol2005; 44: 265–276.
3.
KubanDALevyLBCheungMR. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?Int J Radiat Oncol Biol Phys2011; 79: 1310–1317.
4.
VianiGAStefanoEJAfonsoSL. Higher-than-conventional radiation doses in localized prostate cancer treatment: A meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys2009. 74: 1405–1418.
5.
BollaMde ReijkeTMVan TienhovenG. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med2009; 360: 2516–2527.
6.
WilkinsAMossopHSyndikusI. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-Year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol2015; 16: 1605–1616.
7.
PeetersSTHeemsbergenWDKoperPC. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol2006; 24: 1990–1996.
8.
JonesCUHuntDMcGowanDG. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med2011; 365: 107–118.
9.
HorwitzEMBaeKHanksGE. Ten-year follow-up of radiation therapy oncology group protocol 92–02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol2008; 26: 2497–2504.
10.
BollaMVan TienhovenGWardeP. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-Year results of an EORTC randomised study. Lancet Oncol2010; 11: 1066–1073.
11.
PilepichMVWinterKLawtonCA. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys2005; 61: 1285–1290.
12.
D’AmicoAVChenMHRenshawAA. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA2008; 299: 289–295.
13.
MasonMDParulekarWRSydesMR. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol2015; 33: 2143–2150.
14.
WidmarkAKleppOSolbergA. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet2009; 373: 301–308.
15.
MottetNPeneauMMazeronJJ. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: An open randomised phase 3 trial. Eur Urol2012; 62: 213–219.
16.
LeibelSAFuksZZelefskyMJ. The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys1994; 28: 7–16.
17.
AsbellSOKrallJMPilepichMV. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: Analysis of RTOG 77–06. Int J Radiat Oncol Biol Phys1988; 15: 1307–1316.
18.
LawtonCAWinterKGrignonD. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: Updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85–31. J Clin Oncol2005; 23: 800–807.
19.
JamesNDSpearsMRClarkeNW. Survival with newly diagnosed metastatic prostate cancer in the ‘docetaxel era’: Data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol2015; 67: 1028–1038.
20.
BollaMvan PoppelHTombalB. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911). Lancet2014; 380: 2018–2027.
21.
WiegelTBottkeDSteinerU. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96–02/AUO AP 09/95. J Clin Oncol2009; 27: 2924–2930.
22.
StephensonAJScardinoPTKattanMW. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol2007; 25: 2035–2041.
23.
BrigantiAKarnesRJDa PozzoLF. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2–4 pN+ prostate cancer: Results of a matched analysis. Eur Urol2011; 59: 832–840.
24.
AbdollahFKarnesRJSuardiN. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol2014; 32: 3939–3947.
25.
PottersLMorgensternCCalugaruE. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol2005; 173: 1562–1566.
26.
ZelefskyMJKubanDALevyLB. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys2007; 67: 327–333.
27.
StockRGStoneNN. Importance of post-implant dosimetry in permanent prostate brachytherapy. Eur Urol2002; 41: 434–439.
28.
MachtensSBaumannRHagemannJ. Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. World J Urol2006; 24: 289–295.
29.
GalalaeRMKovacsGSchultzeJ. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys2002; 52: 81–90.
30.
KupelianPAPottersLKhuntiaD. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys2004; 58: 25–33.
31.
HoskinPJMotohashiKBownesP. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial. Radiother Oncol2007; 84: 114–120.
32.
PietersBRde BackDZKoningCC. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: A systematic review. Radiother Oncol2009; 93: 168–173.
33.
GrayPJPalyJJYeapBY. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer2013; 119: 1729–1735.
34.
SheetsNCGoldinGHMeyerAM. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA2011; 307: 1611–1620.
35.
PloussardGDaneshmandSEfstathiouJA. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: A systematic review. Eur Urol2011; 66: 120–137.
36.
De NeveWLybeertMLGoorC. Radiotherapy for T2 and T3 carcinoma of the bladder: The influence of overall treatment time. Radiother Oncol1995; 36: 183–188.
37.
MilosevicMGospodarowiczMZietmanA. Radio-therapy for bladder cancer. Urology2007; 69: S80–S92.
38.
TonoliSBertoniFDe StefaniA. Radical radiotherapy for bladder cancer: Retrospective analysis of a series of 459 patients treated in an Italian institution. Clin Oncol (R Coll Radiol)2006; 18: 52–59.
39.
ChungPWBristowRGMilosevicMF. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol2007; 25: 303–309.
40.
ShelleyMDBarberJWiltT. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev2002: CD002079.
41.
MameghanHFisherRMameghanJ. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys1995; 31: 247–254.
42.
ArcangeliGStrigariLArcangeliS, et al. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. Crit Rev Oncol Hematol2015; 95: 387–396.
43.
EfstathiouJASpiegelDYShipleyWU. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience. Eur Urol2012; 61: 705–711.
44.
ZietmanALSaccoDSkowronskiU. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: Results of a urodynamic and quality of life study on long-term survivors. J Urol2003; 170: 1772–1776.
45.
WidmarkAFlodgrenPDamberJE. A systematic overview of radiation therapy effects in urinary bladder cancer. Acta Oncol2003; 42: 567–581.
46.
El-MonimHAEl-BaradieMMYounisA. A prospective randomized trial for postoperative vs. preoperative adjuvant radiotherapy for muscle-invasive bladder cancer. Urol Oncol2013; 31: 359–365.
47.
ColeCJPollackAZagarsGK. Local control of muscle-invasive bladder cancer: Preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys1995; 32: 331–340.
48.
ChenBZengZCWangGM. Radiotherapy may improve overall survival of patients with T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse. BMC Cancer2011; 11: 297.
49.
CzitoBZietmanAKaufmanD. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol2004; 172: 1271–1275.
50.
DieckmannKPKulejewskiMPichlmeierU. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: Systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol2007; 51: 175–183; discussion 183–185.
51.
Hoei-HansenCERajpert-De MeytsEDaugaardG. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: A clinical review. Ann Oncol2005; 16: 863–868.
52.
KregeSBeyerJSouchonR. European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. Eur Urol2008; 53: 478–496.
53.
ClassenJDieckmannKBambergM. Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: Preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. Br J Cancer2003; 88: 828–831.
54.
DieckmannKPWilkenSLoyV. Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: A survey of the German Testicular Cancer Study Group. Ann Oncol2013; 24: 1332–1337.
55.
TravisLBFossaSDSchonfeldSJ. Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst2005; 97: 1354–1365.
56.
HuddartRANormanAShahidiM. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol2003; 21: 1513–1523.
57.
ChungPWGospodarowiczMKPanzarellaT. Stage II testicular seminoma: Patterns of recurrence and outcome of treatment. Eur Urol2004; 45: 754–759; discussion 759–760.
58.
PattersonHNormanARMitraSS. Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: Comparison with radiotherapy treatment alone. Radiother Oncol2001; 59: 5–11.
CrookJMHaie-MederCDemanesDJ. American Brachytherapy Society-Groupe Europeen de Curietherapie-European Society of Therapeutic Radiation Oncology (ABS-GEC-ESTRO) consensus statement for penile brachytherapy. Brachytherapy2013; 12: 191–198.
63.
De MeerleerGKhooVEscudierB. Radiotherapy for renal-cell carcinoma. Lancet Oncol2014; 15: e170–e177.
64.
DennisKMakhaniLZengL. Single fraction conventional external beam radiation therapy for bone metastases: A systematic review of randomised controlled trials. Radiother Oncol2013; 106: 5–14.
65.
LutzSBerkLChangE. Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys2011; 79: 965–976.
66.
SzeWMShelleyMHeldI. Palliation of metastatic bone pain: Single fraction versus multifraction radiotherapy – a systematic review of the randomised trials. Cochrane Database Syst Rev2002: CD004721.
67.
FurubayashiNNegishiTUraS. Palliative effects and adverse events of strontium-89 for prostate cancer patients with bone metastasis. Mol Clin Oncol2015; 3: 257–263.
68.
ParkerCCPascoeSChodackiA. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol2013; 63: 189–197.
69.
SrinivasanVBrownCHTurnerAG. A comparison of two radiotherapy regimens for the treatment of symptoms from advanced bladder cancer. Clin Oncol (R Coll Radiol)1994; 6: 11–13.
70.
KothariGForoudiFGillS. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: A systematic review. Acta Oncol54: 148–157.
